GlaxoSmithKline Shs Sponsored American Deposit Receipt Repr 2 Shs $52.82

up +0.50


16/4/2014 04:03 PM  |  NYSE : GSK  
Industries : Drugs / Drug Manufacturers - Major
Get Trend Analysis Icon Get GSK Trend Analysis - it has underperformed the S&P 500 by 12%

Partner Headlines

  1. Race for Vaccines, Treatments as West Africa Ebola Death Toll Tops 100

    Benzinga
  2. Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With The Highest ...

    Benzinga
  3. GlaxoSmithKline

    IBD
  4. Amgen, GSK End Marketing Pact for Osteoporosis Drug

    FoxBusiness
  5. Biotech Auxilium Boosts Position In Men's Health Care

    IBD
  6. Glaxosmithkline Confirms Warning Letter Received from FDA o March 19, 2 ...

    Benzinga
  7. GSK buys up Indonesia unit

    IBD
  8. GSK Recalls Alli in U.S. After Package Tampering

    FoxBusiness
  9. GSK, FDA Probe Tampering of Weight-Loss Drug Alli

    FoxBusiness
  10. Which Pharmas Can Keep Up Dividend-Buybacks?

    YCharts
  11. Market Wrap For March 20: Investors Showing No Post-Fed Decision Hangover

    Benzinga
  12. Glaxo Cancer Vaccine Fails, Testing Continues

    FoxBusiness
  13. Morning Market Losers

    Benzinga
  14. US Stock Futures Drop Ahead Of Jobless Claims Report

    Benzinga
  15. Agenus Therapeutics Reports GlaxoSmithKline's Magrit Study Does Not Meet ...

    Benzinga
  16. T. Rowe Price's Brian Rogers Joins GuruFocus for Q&A - Ask an Investing ...

    GuruFocus
  17. T. Rowe Price CIO Brian Rogers Joins GuruFocus for Q&A - Ask an Investing ...

    GuruFocus
  18. Gilead's HCV Challengers Near The Starting Gate

    IBD
  19. Brian Rogers of T. Rowe Price Joins GuruFocus for Q&A - Ask a Question

    GuruFocus
  20. Gilead's HCV Challengers Near The Starting Gate

    IBD
  21. Prosensa Muscular Dystrophy Data Send Stock Rising

    IBD
  22. A HIV shot could replace pills

    IBD
  23. Why Long-Term Investor Warren Buffett's Company Just Sold 2 Stocks

    GuruFocus
  24. GlaxoSmithKline, Kinder Morgan And Others Insiders Have Been Buying

    Benzinga
  25. Glaxo's COPD Drug Gets European Green Light

    FoxBusiness
  26. Berkshire Hathaway Files SEC 13F

    Benzinga
  27. Pharmacyclics' Imbruvica Wins Second Cancer Approval

    IBD
  28. Novartis' 'Cliffy' Business

    GuruFocus
  29. Glaxo expects to retain lead

    IBD
  30. Benzinga Weekly Preview: Twitter To Release Earnings For The First Time ...

    Benzinga
  31. Ariad Shares Continue to Surge Amidst Buyout Rumors

    Benzinga
  32. Tweedy Browne Global Value Fund New Buy and Adds

    GuruFocus
  33. Pharmacyclics: Facts Behind $10B Market Cap

    YCharts
  34. $10B Market By 2022: Pharmacyclic’s Piece Of It

    YCharts
  35. Bristol-Myers: Don't Let This One Get Away

    GuruFocus
  36. AstraZeneca: Time to Make a Bet? Steven Cohen Seems to Think It Is

    GuruFocus
  37. Morning Market Losers

    Benzinga
  38. Benzinga's Top #PreMarket Losers

    Benzinga
  39. Pharmacyclics, Valeant, Celgene Up On Bullish News

    IBD
  40. PharmacyclicsDrug Trial To End Early On Strong Data

    IBD
  41. Stock Futures Positive, Steady; Netflix Dives On Downgrade

    IBD
  42. New Drugs Could Change Cancer Landscape In 2014

    IBD
  43. ObamaCare = Drug Maker Assistance Act

    YCharts
  44. Why MasterCard, Up 64% in 2013, Isn’t Done

    YCharts
  45. Merck’s Bad-Mouthing Of Generic: $21 Million Fine

    YCharts
  46. Prosensa Comments on Drisapersen Program Update

    Benzinga
  47. Merck Collaborates with GlaxoSmithKline on MK-3475

    Benzinga
  48. Glaxo Curbs Drug Promotion

    IBD
  49. Pharma’s Pay-to-Delay Deals Targeted Again

    YCharts
  50. Pfizer’s Great Hope Xeljanz: More Bad News

    YCharts
Trading Center